GeneDx Holdings Corp. (WGS)

NASDAQ: WGS · IEX Real-Time Price · USD
0.297
-0.005 (-1.59%)
At close: Mar 29, 2023, 4:00 PM
0.294
-0.003 (-0.94%)
After-hours: Mar 29, 2023, 7:55 PM EDT
-1.59%
Market Cap 236.76M
Revenue (ttm) 234.69M
Net Income (ttm) -548.98M
Shares Out 798.25M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 3,520,494
Open 0.305
Previous Close 0.301
Day's Range 0.280 - 0.321
52-Week Range 0.220 - 3.280
Beta 1.87
Analysts Buy
Price Target 1.47 (+395.62%)
Earnings Date May 11, 2023

About WGS

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights. It also provides genetic diagnostic tests, screening solutions, and information with a focus on pediatrics, rare diseases for children and adults, and hereditary cancer screening. GeneDx Holding... [Read more]

Sector Healthcare
Founded 2017
Employees 1,200
Stock Exchange NASDAQ
Ticker Symbol WGS
Full Company Profile

Financial Performance

In 2022, WGS's revenue was $234.69 million, an increase of 10.60% compared to the previous year's $212.20 million. Losses were -$548.98 million, 123.7% more than in 2021.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for WGS stock is "Buy." The 12-month stock price forecast is $1.47, which is an increase of 395.62% from the latest price.

Price Target
$1.47
(395.62% upside)
Analyst Consensus: Buy
Stock Forecasts

News

GeneDx Announces Progress on GUARDIAN Study and Promise of Early Genomic Testing to End Rare Disease “Diagnostic Odyssey”

STAMFORD, Conn., March 20, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp (GeneDx) (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced ...

1 week ago - GlobeNewsWire

The 7 Worst Stocks to Buy Now

Generally, I dislike writing about the worst stocks to buy now (or similar themes) because it invariably offends members of the internet defense league. It's not the greatest experience to receive a f...

1 week ago - InvestorPlace

GeneDx Presents New Data at ACMG Demonstrating the Benefits of Exome Sequencing Over Chromosomal Microarray

New research released at ACMG Annual Clinical Genetics Meeting reiterates the superiority of exome sequencing's role in shortening the diagnostic odyssey New research released at ACMG Annual Clinical ...

1 week ago - GlobeNewsWire

GeneDx Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Financial results are in line with previously announced preliminary 2022 results; Reiterating 2023 guidance, including total revenue of $205-220 million

2 weeks ago - GlobeNewsWire

GeneDx to Participate in the Cowen 43rd Annual Healthcare Conference

STAMFORD, Conn., March 01, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that company management...

1 month ago - GlobeNewsWire

GeneDx honors Rare Disease Day and announces presentations and research at the 2023 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

Research illustrates company's progress in working to end the diagnostic odyssey and includes data with implications for how care is delivered to patients beginning at birth Research illustrates compa...

1 month ago - GlobeNewsWire

GeneDx to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14th, 2023

STAMFORD, Conn., Feb. 21, 2023 (GLOBE NEWSWIRE) -- GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced it will release financia...

1 month ago - GlobeNewsWire

GeneDx Rare Disease Data Demonstrates Utility in Drug Candidate Identification for Common Diseases

Research published in Nature Genetics underscores the role of genetic insights in the drug discovery and development process Research published in Nature Genetics underscores the role of genetic insig...

1 month ago - GlobeNewsWire

GeneDx Announces Closing of Underwritten Public Offering and Concurrent Registered Direct Offering

STAMFORD, Conn., Jan. 31, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the closing of its previously announced underwritten public offering of shares of its Class A com...

2 months ago - GlobeNewsWire

GeneDx Makes Significant Industry-Wide Contributions to New Disease Gene Discovery

Company submitted nearly one quarter of all candidate gene submissions to GeneMatcher in 2022 and collaborated on 63 publications involving new disease-gene associations or expansion of phenotype disc...

2 months ago - GlobeNewsWire

Why Is GeneDx (WGS) Stock Down 8% Today?

GeneDx (NASDAQ: WGS) stock is taking a beating on Friday after the company revealed a proposed public stock offering. According to a press release, GeneDx intends to raise $150 million from the offer...

2 months ago - InvestorPlace

GeneDx Holdings Announces Pricing Of A $150 Million Underwritten Public Offering Of Class A Common Stock And Concurrent Registered Direct Offering

STAMFORD, Conn., Jan. 27, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS) today announced the pricing of offerings for an aggregate of 428,571,429 shares of its Class A common stock at a ...

2 months ago - GlobeNewsWire

GeneDx Announces Proposed Underwritten Public Offering of Class a Common Stock and Concurrent Registered Direct Offering

STAMFORD, Conn., Jan. 26, 2023 (GLOBE NEWSWIRE) -- GeneDx Holdings Corp. (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic and clinical insights, today announced that it i...

2 months ago - GlobeNewsWire